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Abstract
Cervical cancer is the third most common cancer in women worldwide. Persistent infection with high-risk HPV types,
principally HPV16 and 18 is the main risk factor for the development of this malignancy. However, the onset of invasive
tumor occurs many years after initial exposure in a minority of infected women. This suggests that other factors beyond
viral infection are necessary for tumor establishment and progression. Tumor progression is characterized by an increase in
secretion and activation of matrix metalloproteinases (MMPs) produced by either the tumor cells themselves or tumor-
associated fibroblasts or macrophages. Increased MMPs expression, including MMP-2, MMP-9 and MT1-MMP, has been
observed during cervical carcinoma progression. These proteins have been associated with degradation of ECM
components, tumor invasion, metastasis and recurrence. However, few studies have evaluated the interplay between HPV
infection and the expression and activity of MMPs and their regulators in cervical cancer. We analyzed the effect of HPV16
oncoproteins on the expression and activity of MMP-2, MMP-9, MT1-MMP, and their inhibitors TIMP-2 and RECK in cultures
of human keratinocytes. We observed that E7 expression is associated with increased pro-MMP-9 activity in the epithelial
component of organotypic cultures, while E6 and E7 oncoproteins co-expression down-regulates RECK and TIMP-2 levels in
organotypic and monolayers cultures. Finally, a study conducted in human cervical tissues showed a decrease in RECK
expression levels in precancer and cancer lesions. Our results indicate that HPV oncoproteins promote MMPs/RECK-TIMP-2
imbalance which may be involved in HPV-associated lesions outcome.
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Introduction
Cervical cancer is the third most commonly diagnosed
malignancy and the fourth leading cause of cancer death in
females worldwide. It accounts for 9% (529,800) of the total new
cancer cases and 8% (275,100) of the total cancer deaths among
females [1]. Molecular and epidemiological studies have estab-
lished that persistent infection with high-risk human papillomavi-
ruses (HR-HPVs) types is the main risk factor for the development
of cervical cancer and its precursor lesions [2,3]. HPVs are small
DNA viruses that encode two viral oncoproteins, E6 and E7. The
best characterized properties of E6 and E7 proteins from HR-
HPVs are their capacity to mediate the degradation of p53 and
pRb, respectively. Besides, these viral proteins interact with other
several cellular factors abrogating normal cell cycle checkpoints
and cell death mechanisms [4,5]. E6 and E7 are essential for
establishment and progression of cervical cancer precursor lesions
being the only viral products consistently expressed in cervical
cancer derived cell lines. Importantly, their continuous expression
is required to maintain the transformed phenotype in vitro [6,7].
Progression of most solid tumors is characterized by an increase
in secretion and activation of matrix metalloproteinases (MMPs)
produced by either the tumor cells or tumor-associated fibroblasts
[8,9]. These proteins play a central role in diverse physiological
processes and diseases such as homeostatic tissue remodeling and
cancer. Proteolytic activity of MMPs can be regulated at different
levels including gene expression, protein compartmentalization,
zymogen to active enzyme conversion and by the presence of
specific inhibitors [10,11]. Tissue or extracellular MMPs are
regulated by endogenous inhibitors named tissue inhibitor of
metalloproteinases 1 to 4 (TIMP-1–4). Among them, TIMP-2 is
unique since it may function both as a MMP inhibitor and
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activator [9]. Besides, REversion-inducing Cysteine-rich protein
with Kazal motifs (RECK), a membrane bound protein, can exert
inhibitory effects on the transcription, synthesis, activation and
activity of MMPs [12,13,14]. RECK gene is expressed in various
normal organs and has been found to be important in suppressing
tumor invasion, metastasis and angiogenesis [12,13,15]. Several
studies have shown that RECK levels are significantly down-
regulated in human pancreatic, mammary, lung, prostate, and
colorectal cancers, as well as in hepatocarcinoma and neuroblas-
toma, compared with the normal surrounding tissue [16–22].
Importantly, detection of normal or elevated RECK levels in
tumor samples has been associated with decreased invasiveness
and metastatic potential and with improved prognosis as well [23].
Increased MMPs expression, including MMP-2, MMP-9 and
MT1-MMP, has been observed during cervical carcinoma progres-
sion. These proteins have been detected in tumor and peritumoral
stroma cells and associated with degradation of extracellular matrix
(ECM) components. Moreover, their involvement in tumor invasion
process, metastasis and tumor recurrence has been described [24–
28]. However, few studies have evaluated the interplay between HPV
infection and the expression and activity of different MMPs and their
regulators in cervical carcinogenesis [29,30].
In the present study we analyzed the effect of HPV16
oncoproteins on the expression and activity of MMP-2, MMP-9,
MT1-MMP, TIMP-2 and RECK in monolayer and organotypic
cultures of human keratinocytes. We observed that E7 expression
is associated with increased pro-MMP-9 activity in the epithelial
component of organotypic cultures. Besides, we show that E6 and
E7 co-expression down-regulates RECK and TIMP-2 levels in
organotypic and monolayers cultures. Interestingly, immunohis-
tochemical analysis in human cervical tissues show a decrease of
RECK levels in precancer and cancer lesions. Altogether, our
results support the notion that HPV infection, through the
expression of E6 and E7, promotes MMPs/RECK-TIMP-2
imbalance that may affect HPV-associated lesions outcome.
Materials and Methods
Cell lines and Retrovirus derived Vectors
Human cervical carcinoma-derived cell lines (SiHa, CaSki,
C33A), human fibrosarcoma-derived cell line (HT1080) and
murine fibroblasts J2 (NIH 3T3, ATCC: CRL1888) were obtained
from the American Type Culture Collection (Manassas, VA,
USA). The primary culture of human fibroblasts (FF 287) was a
gift from Dr. Marı´a Soengas (Centro Nacional de Investigaciones
Oncolo´gicas CNIO / Spanish National Cancer Research Center,
Madrid, Spain). Cell cultures were maintained in DMEM
supplemented with 10% FBS. Low passage-pooled neonatal
human foreskin keratinocytes (HFK) (Lonza Walkersville, Inc.,
Walkersville, MD, USA) were cultured in keratinocytes serum-free
medium (KSFM, Invitrogen, Frederick, MD, USA).
pLXSN-based retroviral vectors (access Number M28248,
GeneBank) containing HPV16 E6 and/or E7 wild type sequences
were a kind gift from Dr. Denise A. Galloway (Division of Human
Biology, Fred Hutchinson Cancer Research Center, Seattle, WA,
USA). Human foreskin keratinocytes were infected with retroviral
particles containing pLXSN vector alone or HPV16 E6 and/or E7
oncogenes. After 24 hours, the cells were selected with 300 mg/ml
of G418 for 2 days. Surviving cells were amplified and used to seed
organotypic or monolayers cultures.
Organotypic raft cultures
pLXSN, E6wt, E7wt and E6E7 transduced HFK cell lines were
differentiated in organotypic raft cultures for 9–11 days at the
medium-air interface as described previously [31]. The cultures
were harvested, fixed in 10% buffered formalin, embedded in
paraffin, and cut into 4-mm histological sections.
Tissue samples
Cervical tissue samples were obtained from the Laboratory of
Medical Investigation (LIM) 14, Department of Pathology, Sa˜o
Paulo University School of Medicine, Brazil, and from the
Pathology Division, Adolfo Lutz Institute, Sa˜o Paulo, Brazil.
Ethical approval for this study was granted by the Comiteˆ de E´tica
em Pesquisa do Instituto Adolfo Lutz (CEPIAL – Research Ethical
Committee of Adolfo Lutz Institute). There was no informed
consent because tissue samples were selected retrospectively from a
routine pathology archive, in a completely anonymous way. All
the samples were older than three years. Therefore, it was not
possible to track back written informed consent of the patients. A
total of 17 paraffin-embedded cervical tissue specimens and 49
TMA (Tissue Micro Array) were analyzed for RECK staining.
These samples included 16 cervicitis, 20 cervical intraepithelial
neoplasias grade I (CIN I), 18 CIN II/III and 12 invasive
carcinomas.
Western Blot analysis and gelatin Zymography
After 11 days at the liquid–air interface, epidermis from raft
cultures were detached from the collagen matrix (dermal
equivalent) with a scalpel and frozen in liquid nitrogen. Epithelial
tissues from two cultures were minced in a tissue grinder
containing 200 ml of cold lysis buffer: 50 mM Tris pH 7.4,
150 mM NaCl, 1% Triton X-100, 1 mM EDTA, and proteases
inhibitors (Protease inhibitor cocktail tablets; Roche, Mannheim,
Germany). After 15 min on ice, the tubes were centrifuged for
20 min at 100006 g and 4uC to separate the insoluble material.
Cell lines and transduced keratinocytes grown in monolayer were
lysed in the same cold lysis buffer. Protein concentrations were
determined by a commercial protein assay (Bio-Rad Laboratories,
Hercules, CA, USA). Equivalent amounts of protein (25 mg for
MMPs blots and 50 mg for RECK blots) were resolved by SDS-
PAGE (8–10%) and transferred to polyvinylidene difluoride
membranes (Amersham Pharmacia Biotech, Buckinghamshire,
UK) using the Mini Trans-blot Electrophoretic Transfer system
(Bio-Rad Laboratories, Hercules, CA, USA). Membranes were
blocked for 1 h in 5% non-fat milk and probed overnight with the
following primary antibodies: anti-MMP-2 (MAB3308) at 1:1000,
anti-MMP-9 (MAB13415) at 1:100, anti-MT1-MMP (AB8345) at
1:250, all three from Chemicon (Temecula, CA, USA); anti-
RECK (611512,BD Biosciences; San Jose, CA, USA) at 1:250.
Expression of b-actin and a-tubulin was used as a loading control
and detected with anti-actin (a5441) and anti-tubulin (t5168) both
from Sigma (St Louis, MO, USA). Membranes were washed and
then reprobed with horseradish peroxidase (HRP)-conjugated
secondary antibodies. The bands were revealed using Enhanced
Chemiluminescence procedures according to the manufacturer’s
recommendations (Amersham Pharmacia Biotech, Buckingham-
shire, UK). Samples from HT1080 (human fibrosarcoma) and
FF287 (human fibroblast) were used as positive controls for MMPs
and RECK, respectively.
Gelatinolytic activity was examined by gelatin zymography.
Equal amounts of total proteins extracts from rafts epidermis and
dermis were separated on 10% SDS-PAGE gels containing 1 mg/
ml gelatin. The gels were washed twice in 2.5% Triton X-100 at
37uC and incubated overnight at 37uC in reaction buffer (0.05 M
TrisHCl, pH = 8.5, 10 mM CaCl2, 1 mM ZnCl2). Gels were
submitted to stain with coomassie solution (0.5% Coomassie
brilliant blue R-250, in 10% methanol, and 10% acetic acid) and
HPV16 Oncoproteins on MMPs/RECK-TIMP-2 Imbalance
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destained in 10% methanol/10% acetic acid. Clear zones of
gelatin lysis against a blue background stain indicated the presence
of MMPs. Each lysis zone within a given sample lane was analyzed
using Image J software (National Institute of Health, Bethesda,
Maryland, USA).
Measurement of MMP-2 and MMP-9 activity
MMP-2 and MMP-9 activity was quantified in the culture
supernatants from monolayer cultures of HFK transduced with
retroviral vectors expressing HPV16 oncoproteins using specific
Biotrak assay systems (MMP-2 Biotrak Activity Assay RPN 2631;
MMP-9 Biotrak Activity Assay RPN2634, GE Healthcare,
Buckinghamshire, UK) according to the manufacturer’s instruc-
tions. One hundred micrograms of total protein from the
corresponding culture medium was added to each well of the
Biotrak plates. The absorbance was measured by spectrophotom-
etry at 405 nm. MMP-2 and MMP-9 activities were calculated
using standards provided by the kit and expressed as ng/ml. The
detection limits of the assay are 0.75–12 ng/ml for MMP-2 and
0.125–16 ng/ml for MMP-9. Each cell line was analyzed in
triplicate.
Immunofluorescence
Transduced HFK were plated on glass coverslips, fixed with 4%
paraphormaldehyde in phosphate-buffered saline (PBS), washed
with PBS, and permeabilized with 0.2% Triton X-100 in PBS for
5 min at room temperature (RT). Cells were then blocked with 5%
bovine serum albumin in PBS at RT for 30 min and incubated for
one hour with anti-RECK (BD Biosciences, San Jose, CA, USA) at
1:50 dilution in blocking solution at RT. An Alexa Fluor 488-
conjugated goat anti-mouse antibody was used as secondary
antibody (1:200; A-11001, Molecular Probes, CA, USA). Nuclei
were counterstained with 49,6-diamino-2-phenylindole (DAPI,
Molecular Probes, CA, USA). Sections were mounted with ProLong
Antifade Kit (P7481, Molecular Probes, CA, USA). Images were
captured with a Nikon Eclipse S100 fluorescence microscope, with
Metamorph (6.0, Molecular Devices, PA, USA) software (DAPI:
100 ms and Alexa 488: 600 ms). The primary antibody was omitted
in the preparation of negative control coverslips.
TIMP-2 ELISA assay
Culture supernatants obtained as described before were
examined for expression of TIMP-2 using a sandwich enzyme-
linked immunosorbent assay (TIMP-2, Human, Biotrak ELISA
System RPN 2618, GE Healthcare, Buckinghamshire, UK)
according to the manufacturer’s instructions. Briefly, 100 mg of
total protein from the corresponding culture medium or the
supplied standards were incubated with a peroxidase labeled Fab9
antibody to TIMP-2. Immediately, samples were added to
microtitre wells pre-coated with anti-TIMP-2 antibody and
incubated for 2 h at room temperature. The wells were rinsed
with washing solution, and TMB substrate (tetramethylbenzidine)
was added. The reaction was stopped by the addition of 1 M
sulfuric acid. The absorbance of each well was measured by
spectrophotometry at 450 nm and plotted against a standard
curve with TIMP-2 levels expressed as ng/ml. The lower detection
limit of this assay is 5.0 ng/ml. Each cell line was analyzed in
triplicate.
Immunohistochemical staining of organotypic cultures
and tissue samples
Paraffin-embedded organotypic cultures and tissue samples
sections were deparaffinized in xylene and rehydrated in alcohol.
After antigen retrieval with citrate buffer (pH 6.0) sections were
incubated with 3% hydrogen peroxidase in PBS to block
endogenous peroxidase activity. Tissue samples were additionally
blocked with 10% horse serum (Gibco - #16050130, Carlsbad,
CA,USA). Sections were incubated overnight at 4uC with an anti-
RECK monoclonal antibody (611512 / BD Biosciences; San Jose,
CA, USA) at 1:100 in 2% bovine serum albumin-phosphate
buffered solution for organotypic cultures, or at 1:75 in 5% horse
serum phosphate buffered solution for cervical tissue samples.
After washing in PBS, the organotypic cultures sections were
incubated with the LSAB+ System-HRP –K0690 kit (DAKO
Cytomation, CA, USA) and cervical tissue samples with
Histostain-SP broad spectrum secondary antibody (Zymed
Laboratories, South San Francisco, USA), according to the
manufacturer’s instructions. Slides were developed using 3,39-
diaminobenzidine tetrahydrochloride (Dako Cytomation Liquid
DAB+substrate Chromogen System Kit, K-3467, Dako North
America, CA, USA, or D-5637, Sigma, USA) and counterstained
with Harry’s hematoxylin. An irrelevant mouse IgG was used in
the preparation of negative control slides. Human skin samples
were used to prepare positive control slides. In cervical tissue
samples RECK-expression was estimated as follows: Grade 0, no
staining; Grade 1, faint staining; Grade 2, moderate staining;
Grade 3, strong staining, for membrane and cytoplasmic
detection. To facilitate the analyses, tumors were classified based
on the intensity and localization of the staining, into the following
three groups: RECK-weak tumors (Grades 0–1 at membrane),
RECK-strong tumors (Grades 2–3 at membrane) and RECK
cytoplasmic (Grades 1, 2 and 3 at cytoplasm). The images were
captured with an Olympix DP70 digital camera attached to an
Olympus Provis IX70 microscope with Image-Pro Plus 5.0
software.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was isolated from transduced keratinocytes with
RNeasy MiniKit (Qiagen, Valencia, CA, USA), according to the
manufacturers protocol. RNA was quantified spectrophotometri-
cally (ND-1000 – NanoDrop- Wilmington, DE, USA). One
microgram of total RNA, previously treated with 1unit/mL DNAse
I, was reverse transcribed using 0.5 mg/mL of oligo-dT primers,
100 ng/mL of random hexamers and 200 units/mL of M-
MuLVRT reverse transcriptase (Fermentas, Glen Burnie, MD,
USA) and the resulting cDNA was diluted 120-fold. Specific
primers for human RECK: F: 59- TGCAAGCAGGCATCTT-
CAAA - 39 and R: 59- ACCGAGCCCATTTCATTTCTG - 39,
and Tubulin: F: 59- TCAACACCTTCTTCAGTGAAACG - 39
and R: 59- AGTGCCAGTGCGAACTTCATC - 39, were
designed using Primer3 software and synthesized by IDT Inc,
(Coralville, IA, USA). Tubulin was used to normalize the amount
of total human cDNA. Reactions were carried out in a 7500 Real-
Time PCR System (PE - Applied Biosystems, Scoresby, Australia).
The PCR conditions and relative gene expression analysis were
described previously [29,32].
Statistical Analysis
Statistical analysis was performed with GraphPad Prism 5
(GraphPad Software, Inc., CA, USA). The significance of detected
expression or activities differences was calculated by One-way
ANOVA followed by a multiple comparison test (Tukey test). All
the experiments were performed at least three times, and the total
number of experiments is indicated in the figure legend. Data are
expressed as mean 6 SE. Statistical significance was defined as
P,0.05.
HPV16 Oncoproteins on MMPs/RECK-TIMP-2 Imbalance
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e33585
Results
MMP-9 activity is up-regulated in organotypic cultures
expressing HPV16 E7
We have previously shown that expression of MMP-9 and
MT1-MMP is higher in HPV positive than in HPV negative
cervical cancer derived cell lines [29]. This prompted us to analyze
the individual and combined effect of HPV oncoproteins on the
level and activity of MMP-2, MMP-9 and MT1-MMP in HFKs
grown in monolayer. We observed that HPV16 oncoproteins do
not affect the level or activity of these MMPs in monolayer cultures
of HFKs (Figure S1).
HPV life cycle is tightly associated to stratified epithelial
differentiation and many effects of viral oncoproteins take place in
the suprabasal layers of squamous epithelia. Therefore, we
investigated the impact of viral oncoproteins on the expression
of MMP-2, MMP-9 and MT1-MMP in epithelial organotypic
cultures. The relative amounts and activity of latent and activated
MMP-9 and MMP-2 molecular species were assessed by western
blot and gelatin zimography, respectively, in of epidermis
(stratified keratinocytes) or dermis (fibroblast and type I collagen
gel) from organotypic cultures expressing HPV16 oncoproteins
(Figure 1). Gelatinolytic activity was detected in bands around
92 kDa (pro-MMP-9), 82 kDa (active MMP-9), 72 kDa (pro-
Figure 1. HPV-16 E7 up-regulates MMP-9 activity in organotypic cultures. Primary HFKs were transduced with pLXSN-based retroviral
vectors expressing HPV16 E6wt and/or E7wt. Cells were then differentiated in organotypic cultures for 9 to 11 days. A, Determination of gelatinase
activity in organotypic cultures homogenates (epidermis separated from dermis). Equal amounts of proteins were loaded. Note the increase in MMP-9
gelatinase activity in HPV-16 E7wt and E6E7- expressing epidermis. B-B9, densitometry of pro-MMP-9 bands in epidermis and dermis, respectively. C,
MMP-9 levels in epidermis homogenates were determined by Western blot. P,0.05.
doi:10.1371/journal.pone.0033585.g001
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MMP-2), 66 kDa (intermediary form MMP-2) and 62 kDa (active
MMP-2) (Fig. 1A). Among epidermal samples, those derived from
HPV16 E7wt and E6E7 expressing cultures exhibited higher
MMP-9 activity (both latent and active forms, P,0.05) (Figure 1A,
1B). For samples derived from the dermal equivalent, MMP-9
latent form was detected in all conditions. MMP-9 activity was
down-regulated in samples from cultures expressing E7wt alone
(P,0.05). However, no significant differences were detected when
comparing samples from E6E7 expressing cultures with control
(Figure 1B9). Importantly, MMP-9 activity detection was strictly
dependant on the co-culture with keratinocytes, since its activity
was undetectable in dermal equivalents cultured in the absence of
an overlying epidermal component (Figure 1A). Latent, interme-
diate and active MMP2 forms were detected in all epidermal and
dermal equivalent samples analyzed. Overall, dermal equivalent
samples exhibited higher MMP-2 activity than epidermal ones.
This is an expected result, since dermal equivalents are composed
of type I collagen, a MMP-2 activity inducer [33]. In this case, no
differences in MMP-2 activity were observed in dermal equivalents
cultures in the absence of keratinocytes (Figure 1A).
We also used immunoblots to determine MMP-9 expression
levels in the same organotypic cultures samples. As shown in
Figure 1C, active MMP-9 protein expression was detectable in all
samples. Samples from cultures expressing E7wt alone exhibited
higher pro-MMP-9 levels. However, no significant differences in
pro-MMP-9 were detected when comparing samples from E6E7
expressing cultures with control cells.
Our observations indicate that HPV16 E7wt induces MMP-9
activity in keratinocytes grown in a 3-D culture environment but
not in monolayer cultures.
Figure 2. HPV16 oncoproteins down-regulate RECK and TIMP-2 in HFKs. A, Monolayer cultures of primary HFKs were transduced with
pLXSN-based retroviral vectors expressing HPV16 E6wt and/or E7wt. RECK levels were determined by Western blot. Beta-actin was used as loading
control. FF287 cell line was used as a positive control. B, Immunofluorescence detection of RECK (green) in HFKs expressing HPV oncoproteins. RECK is
clearly detected in control and HPV16 E6wt expressing HFKs, while E7wt and E6E7-expressing cells exhibit reduced protein levels (arrows). Nuclei
were counterstained with DAPI (blue). Original magnification 10006. C, TIMP-2 was determined by ELISA (Biotrak). P,0.05.
doi:10.1371/journal.pone.0033585.g002
Figure 3. Expression of HPV-16 E6/E7 down-regulates RECK in organotypic cultures. A, Representative immunoreactivity of RECK in
control and HPV16 E6E7 expressing rafts cultures. Note the strong RECK membrane staining pattern (black arrow) in control compared to the faint
staining in HPV16 E6E7 expressing rafts cultures. B, Quantitative real-time PCR (qRT-PCR) of RECK expression in organotypic cultures. The relative
expression levels were normalized to tubulin. Bars represent the means of triplicate experiments; bars, 6SE.
doi:10.1371/journal.pone.0033585.g003
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HPV-16 E7 expression down-regulates RECK and TIMP-2
in primary HFKs
The results described above indicate that HPV16 E7 induces
MMP-9 expression and activity in primary keratinocytes.
Therefore, we decided to analyze if this viral oncoprotein has an
effect on the MMPs regulators RECK and TIMP-2. RECK is a
(GPI)-anchored glycoprotein that negatively regulates matrix
metalloproteinases, including MMP-9 [12,13,14]. RECK expres-
sion was determined by immunoblot in HFKs transduced with
HPV16 oncoproteins and in three human cervical cancer-derived
cell lines (SiHa, CaSki and C33A). As shown in Figure 2A, RECK
was clearly detected in HFKs transduced with E6wt and control
vector. Conversely, lower levels of this protein were observed in
HFKs expressing HPV16 E7 or E6E7 and in cervical cancer-
derived cell lines (Figure 2A).
These observations were confirmed by immunofluorescence
analysis. As shown in Figure 2B, RECK was detected at high levels
in pLXSN and E6wt transduced-keratinocytes but was expressed
at very low levels in E7wt and E6E7 transduced-cells (Figure 2B).
Strong anti-RECK signal was observed in the perinuclear region
and cytoplasm of keratinocytes transduced with pLXSN and E6wt
HFKs. On the other hand, HPV16 E7wt and E6E7 expressing
cells exhibited a faint RECK staining that was restricted to cell
membrane (Figure 2B). Interestingly, the levels of a second MMP
regulator, TIMP-2, were also down-regulated in HFKs transduced
with HPV16 E6E7 when compared to control cells (Figure 2C)
(P,0,05).
Finally, we observed that RECK expression was clearly detected
in cells from the upper third of the spinous and granular layers of
control organotypic cultures (Fig. 3A). On the other hand, cultures
expressing E6/E7 oncogenes exhibited a faint RECK immuno-
staining (Fig. 3A). This result correlates with reduced RECK
mRNA levels in these cultures (Fig. 3B), suggesting that the
mechanism of down-regulation occurs, at least in part, at the
transcriptional level. Altogether, our results indicate that HPV16
oncoproteins contribute to the down regulation of at least two
different MMPs regulators.
RECK is down-regulated in CIN III and invasive cervical
carcinoma samples
The results described above prompted us to analyze if RECK
down-regulation may occur in vivo in the context of cervical
pathology. For this purpose, RECK levels were determined in
cervical biopsies from patients with cervicitis (n = 16), cervical
intraepithelial neoplasia grade I (CIN I) (n = 20), CIN II/III
(n = 18) and invasive carcinoma (n = 12). Down-regulation of
RECK was observed in nearly all invasive carcinoma (92%) and
half of the (50%) CIN II/III cases. On the other hand, most of the
cervicitis (87.5%) and CIN I (80%) samples exhibited strong
RECK signal (Table 1).
Figure 4 shows a representative immunostaining for RECK in
cervical samples. In cervicitis tissue, strong RECK signal was
observed in the membrane and cytoplasm of most cells in all
cervical epithelium layers (Fig. 4A). On the other hand, CINII/III
and invasive carcinoma samples displayed weak cytoplasmastic
RECK staining throughout the lesion (Fig. 4B–D).
Our observations in cervical samples show that RECK down-
regulation may correlate with lesion grade. Taken together, our
results suggest that inhibition of RECK expression by HPV
oncogenes may play a role during cervical cancer onset/
progression.
Discussion
Deregulated MMP activity plays a critical role during epithelial
carcinogenesis. In this study we show that primary human
keratinocytes expressing HPV16 oncoproteins exhibit up-regulat-
ed MMP-9 activity probably due to E6 and E7 mediated down-
regulation of physiological MMP inhibitors RECK and TIMP-2.
We also show that RECK protein expression is down-regulated in
high-grade cervical lesions and cervical cancer.
Several lines of evidence indicate that MMP-9 plays an important
role in cervical tumor development. Using a murine model of
cervical cancer, Pahler and co-workers showed that macrophages
and neutrophils infiltrating the tumor are the source of the MMP-9
secreted into the tumor stroma [34]. Moreover, a recent study has
shown that HPV-transformed cells can instruct monocytes to
produce MMP-9 through a mechanism involving paracrine STAT3
activation, autocrine CCR2 stimulation and intracellular Ca2+
Table 1. RECK expression in cervicitis, CIN I, CIN II/III and
invasive cervical carcinomas.
Cervicitis CIN I CIN II/III Invasive
Cases (%) 16(100) 20(100) 18(100) 12(100)
Weak* 2(12,5) 4(20) 9(50) 11(92)
Strong** 14(87,5) 16(80) 9(50) 1(8)
n = 66;
*Weak = no staining or faint staining;
**Strong =moderate or strong staining.
doi:10.1371/journal.pone.0033585.t001
Figure 4. RECK is down-regulated in CIN II/III and invasive carcinoma samples. Representative immunoreactivity of RECK in (A) Cervicitis,
(B) cervical intraepithelial neoplasia II (CIN II), (C) cervical intraepithelial neoplasia III (CIN III) and (D) cervical invasive carcinoma. Note the strong RECK
membrane staining pattern in cervicitis (black arrow), a diminished cytoplasmastic staining in CIN II/III and a very weak RECK staining in invasive
carcinoma. Inset in (D): Sample incubated in the absence of primary antibody.
doi:10.1371/journal.pone.0033585.g004
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signaling [35]. Importantly, high MMP-9 expression levels and
activity have been correlated with poor clinical outcome in cervical
cancer patients [26]. Recently, it has been observed that the early
E2 protein of HPV8 increases MMP-9 expression by direct
activation of the MMP-9 promoter [36]. Besides, up-regulation of
MMP-9 possibly trough activation of the MEK/ERK pathway has
been detected in cells expressing HPV-18 E7 [37]. Here we show
that human keratinocytes expressing HPV-16 E7 exhibit up-
regulated MMP-9 activity in organotypic cultures. Since no E2
protein is expressed in our system and no differences in total MMP-
9 protein levels were verified between control and E7 expressing
cells we deduce that E7 mediates MMP-9 activation through an
alternative pathway. These observations suggest that MMP-9 could
be a common target for different HPV types, although different
mechanisms and viral proteins may be involved. Nonetheless our
results show that HPV-infected epithelial cells may be a significant
source of MMP-9 in vivo, a fact that might be important in the
evolution of HPV-associated lesions.
Increased MMP-9 activity may result from at least two no
mutually exclusive processes: increased protein expression/stabil-
ity or decreased MMP-inhibitors levels. Here we show that cells
acutely transduced with HPV-16 oncoproteins display reduced
levels of MMP-inhibitors TIMP-2 and RECK when grown in
monolayer or organotypic cultures. On the other hand, in our
settings, viral oncoproteins did not affect total MMP-9 levels.
TIMP-2 role in cervical carcinoma has been addressed in
previous studies shedding inconclusive results. This inhibitor was
detected as highly expressed in invasive cervical carcinoma tumor
cells and stroma [38]. On the other hand, using a series of 150
cervical carcinomas and 152 CIN lesions Branca and co-workers
observed that TIMP-2 is down-regulated in invasive tumors and
correlated low levels of the inhibitor with poor prognosis and
higher invasive potential [39]. These apparently contradictory
results may reflect the unique TIMP-2 dual role as an inhibitor
and activator of MMPs [9]. Here we show that TIMP-2 may be
down-regulated by acute expression of HPV oncoproteins which
may favor deregulated MMP activity in the context of HPV
infection.
RECK is a membrane bound protein that exerts inhibitory
effects on the transcription, synthesis, activation and activity of
MMPs. In particular, this protein can inhibit the secretion and
activity of MMP-2, MMP-9 and MT1-MMP [12,13,15] as well as
MMP-9 transcription [14]. Down-regulation of RECK has been
documented in many human cancers, including various carcino-
mas, and correlates with aggressiveness and poor prognosis of the
disease [22,23,40]. We have previously shown that RECK mRNA
expression is down-regulated in HPV16-positive cervical carcino-
ma cell lines [29]. Here, we show that these cells lines also present
reduced RECK protein levels. Importantly, down-regulation of
RECK was associated with HPV16 E7 expression. On the other
hand, a recent report showed that HeLa cells where E6 oncogene
was silenced with specific siRNA exhibited up-regulation of several
anti-oncogenes including RECK [30]. These observations suggest
that both oncoproteins may be involved in RECK down-
regulation. Furthermore, they are in line with our results showing
that, in organotypic cultures, co-expression of HPV16 E6 and E7
induce lower levels of RECK than each oncoprotein expressed
individually. Characterization of RECK in human cervical
specimens showed that its expression was higher in cervicitis
samples than in CINII/III and invasive carcinoma samples
indicating that RECK down-regulation may correlate with lesion
grade. Therefore, pending further evaluations, RECK expression
could be a valuable prognostic marker for cervical lesions as has
been proved for other tumors [22,23]. It is worth noting that we
also detected reduced RECK levels in C33A cells, a HPV-negative
cervical cancer cell line. C33A is unique among cervical cancer
derived cell lines in many aspects. For instance, it is p53 mutated.
Obviously, down regulation of p53 activity in this cell line is not
occurring as a consequence of HPV oncoprotein expression.
However, there is little doubt that E6-mediated p53 inhibition is a
critical event in cervical cancer development and maintenance. An
identical line of reasoning can be applied to our observations on
the effect of HPV-16 E7 on RECK expression. Therefore, we
believe that this result further support the notion that RECK
inhibition is an important event in cervical cancer biology. Taken
together, our results indicate that inhibition of RECK expression
by HPV oncogenes may play a role during cervical cancer onset/
progression.
Cells lacking RECK show some characteristics such as decreased
spreading, altered anterior-posterior polarity, increased migration
speed and decreased directional persistence in migration, which are
typical of many transformed cells [41]. On the other hand, RECK
over expression has been associated with actin filaments rearrange-
ment and decreased migratory ability and invasive potential in a
human glioblastoma multiforme model [42]. Although we provide
data that HPV-16 oncoproteins down-regulate RECK expression in
cell cultures and cervical samples, the biological consequences of
low RECK protein expression in the context of HPV-related
diseases remain unknown. Previous work established that TIMP-2
regulates RECK in endothelial cells. Treatment of these cells with
TIMP-2 induced RECK expression through diminished Src levels,
inactivation of Rac1 and activation of Rap1, resulting in a cellular
migration inhibition or directional movement impairment [43,44].
In addition, using a nasopharyngeal carcinoma cellular model Liu
and co-workers showed that the Epstein-Barr-Virus latent protein 1
(LMP1) can down-regulate RECK expression, and that Sp1 binding
site on RECK’s promoter is essential for this effect [45].
Importantly, RECK inhibition confers an invasive and metastatic
phenotype to the cell line. The interplay between HPV oncopro-
teins, TIMP-2 and other cellular factors such as Sp1 and Src in the
regulation of RECK are among the remaining questions arising
from our findings.
Our observations identify a novel property of HPV oncopro-
teins that may favor a pro-tumorigenic environment. First, HPV-
transformed cells can influence MMP-9 expression by tumor
infiltrating myeloid cells. Besides, HPV-infected cells may
contribute directly to MMP-9 activity by E7-dependent up-
regulation of MMP-9 levels and activity. Further local MMP-9
activation can be reached by HPV-oncoproteins mediated down-
regulation of MMP-inhibitors TIMP-2 and RECK. Finally,
TIMP-2 and RECK down-regulation may favor the activation
of other relevant MMPs.
To our knowledge, this is the first report describing RECK
down-regulation in cervical cancer and its inhibition by HPV
oncoproteins in primary keratinocytes. Furthermore, the data in
this study provide the first evidence that HPV-16 E7 may regulate
RECK expression. All in all, our results suggest that RECK down-
regulation may be important in the natural history of cervical
cancer. A systematic investigation of the existence of a correlation
between RECK levels, lesion grade and HPV presence in a larger
set of cervical samples is currently in progress. This study will help
to determine if RECK could represent a new biomarker of cervical
cancer progression and a potential target for therapy.
Supporting Information
Figure S1 Expression of HPV16 E6E7 oncoproteins does
not affect the level and activity of MMP2, MMP9 and
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MT1-MMP in HFKs grown in monolayer. A, Primary HFKs
cultured in monolayer were transduced with pLXSN-based
retroviral vectors expressing HPV-16 E6wt and/or E7wt. Western
blots were carried out to determine MMP-2, MMP-9 and MT1-
MMP levels. Beta-actin was used as a loading control. Extracts
from HT1080 cell line was used as a positive control (n = 3). MMP-
2 (B) and MMP-9 (C) activities were analyzed by Biotrak Activity
Assay. See M&M for details. Significant 2-fold activation of MMP-
9 was observed in supernatants from the HFKs expressing HPV-
16 E6wt when compared to control cells. However, no differences
in MMPs activities were observed between HFKs expressing both
HPV-16 oncoproteins and those transduced with the empty vector
(pLXSN). P,0.05.
(TIFF)
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